[Clinical results with MGDF].
Martín
G
G
Servicio de Hematología, Hospital Universitario La Fe, Valencia.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003606:Dacarbazine / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D015376:Nimustine / Q000008:administration & dosage; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D013921:Thrombocytopenia / Q000139:chemically induced / Q000628:therapy*; D013926:Thrombopoietin / Q000009:adverse effects / Q000627:therapeutic use*; D014750:Vincristine / Q000008:administration & dosage
D011994:Recombinant Proteins; C103117:polyethylene glycol-recombinant human megakaryocyte growth and development factor; D015376:Nimustine; D011092:Polyethylene Glycols; D014750:Vincristine; D003606:Dacarbazine; D013926:Thrombopoietin